AI设计的癌症疫苗加上KEYTRUDA强化了T细胞,并展示了高级黑素瘤患者的临床利益。 An AI-designed cancer vaccine plus KEYTRUDA boosted T-cells and showed clinical benefits in advanced melanoma patients.

Evaxion A/S在国际贸易标准分类2025年会议上分享了其AI设计的癌症疫苗EVX-01的新的第二阶段试验数据,显示该疫苗与KEYTRUDA相结合,导致高级黑瘤患者抗癌T细胞持续增加,这与临床反应相关。 Evaxion A/S shared new phase 2 trial data for its AI-designed cancer vaccine EVX-01 at the SITC 2025 meeting, showing that combining the vaccine with KEYTRUDA® led to a sustained rise in cancer-fighting T-cells in advanced melanoma patients, correlating with clinical responses. 该疫苗是用Evaxion的AI-ImmunologyTM平台建造的,针对的是多个肿瘤特定新抗原。 The vaccine, built using Evaxion’s AI-Immunology™ platform, targets multiple tumor-specific neoantigens. 这些调查结果支持了同一审判早先取得的成效。 These findings support earlier efficacy results from the same trial.